A chemical made by IDH-mutant glioma cells blocks a key fuel
Original title: D-2HG Inhibits Glutamine Synthetase Activity and Induces Senescence in IDH-Mutant Gliomas.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was lab work with cells and tumor samples, not a treatment tested in people.
The short version
Lab work shows IDH gene change: A small change in a tumor's IDH gene. Tumors with this change often grow more slowly and may respond to different treatments. Your pathology report says whether your tumor has it. See the glossary glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary cells struggle when they cannot make enough of a fuel called glutamine.
What was studied. Researchers worked with brain support cells called astrocytes and with glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary cells in the lab. They looked at what the IDH1 mutation does to those cells. They also looked at human glioma tissue samples under the microscope.
What they found. The IDH1 mutation slowed the cells down and pushed them into a worn out, non growing state. The cells also showed DNA damage and more of a stress chemical. Adding glutamine from outside eased these effects. The team found that D-2HG, a chemical made by mutant IDH, blocks the enzyme that cells use to make their own glutamine. In human glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary samples, IDH gene change: A small change in a tumor's IDH gene. Tumors with this change often grow more slowly and may respond to different treatments. Your pathology report says whether your tumor has it. See the glossary tumors had more astrocytes carrying that enzyme, which may feed the tumor cells.
What this means, and what it doesn't
What it could mean: This points to a possible target for future treatment. If the glutamine handoff between support cells and tumor cells could be blocked, IDH gene change: A small change in a tumor's IDH gene. Tumors with this change often grow more slowly and may respond to different treatments. Your pathology report says whether your tumor has it. See the glossary glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary cells might have a harder time growing. It is a clue about how these tumors survive, not a treatment anyone can use today.
What it doesn't mean: This does not mean there is a new treatment. The work was done in cells in the lab and in tumor samples, not in people receiving care. No drug was tested in patients here, and nothing in this study was shown to help anyone live longer or feel better. It is not a cure, and it is a long way from everyday care.
Source: PubMed, August 4, 2025 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.